Keywords: asta, medica, nk, ecco, phase, trial, new

Asta Medica: NK 611 at ECCO 8

Article | 13 November 1995

Print This

- A Phase I trial of Asta Medica's new podophyllotoxin derivative NK 611 has resulted in an appropriate dosing regimen, 10mg/m2/ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in